SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jon Koplik who wrote (1823)3/16/1999 11:04:00 AM
From: RCMac  Read Replies (1) of 2135
 
"Progress Reported in Attacking Tumor Blood Supply", in the NYTimes today, reports the same Duke research, and includes the following:

"biologists at Duke University have now identified sites on blood vessel cells that are probably the receptors to which angiostatin binds. . . .A colleague, Dr. Salvatore Pizzo, said that now that the binding site was known it might be possible to design a small molecule that would home in on it as accurately as angiostatin does."

The article is at nytimes.com

-- RCM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News